ANI Pharmaceuticals, Inc. (ANIP) vs Pacira BioSciences, Inc. (PCRX)
- ANI Pharmaceuticals, Inc. ANIP 72.08 −0.28%
- Pacira BioSciences, Inc. PCRX 36.35 +0.06%
ANI Pharmaceuticals, Inc. and Pacira BioSciences, Inc. are both Drug Manufacturers Specialty & Generic companies. ANI Pharmaceuticals, Inc. is the larger, with a market value of $1.7B against $1.5B — 1.1× the size. ANI Pharmaceuticals, Inc. trades at the lower P/E: 14.9× against 104×. ANI Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 30.9% against 5.71%. ANI Pharmaceuticals, Inc. has the higher net margin (11.0% vs 1.96%) and the higher return on invested capital (11.3% vs 1.58%). Across the 22 metrics below, ANI Pharmaceuticals, Inc. leads on 14 and Pacira BioSciences, Inc. on 8.
Valuation
Profitability
| Metric | ANIP | PCRX | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 60.40% | 79.21% | 53.94% |
| Operating margin | 15.37% | 2.66% | 0.00% |
| Net margin | 11.04% | 1.96% | 0.00% |
| Free cash flow margin | 17.12% | 24.06% | 0.00% |
| Return on equity | 20.88% | 2.05% | (0.40%) |
| Return on assets | 7.61% | 1.05% | (3.32%) |
| Return on invested capital | 11.30% | 1.58% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack